Clinical TrialJun 1, 2026, 07:31 AM
Immuneering Atebimetinib Shows 17.3-Month OS in Pancreatic Cancer
AI Summary
Immuneering Corporation announced updated positive clinical data from its Phase 2a trial evaluating atebimetinib in combination with modified gemcitabine/nab-paclitaxel (mGnP) in first-line metastatic pancreatic cancer. The study demonstrated a median overall survival of 17.3 months in 55 patients, significantly exceeding the 8.5 months observed with standard of care chemotherapy. The treatment also showed a favorable tolerability profile, with limited severe adverse events and 84% of participants maintaining or gaining weight. The company is actively recruiting for its global Phase 3 MAPKeeper 301 trial, with first patient dosing anticipated in mid-2026.
Key Highlights
- Median overall survival (OS) was 17.3 months in 55 first-line pancreatic cancer patients.
- This compares to 8.5 months median OS for standard of care chemotherapy in the pivotal MPACT study.
- Median progression-free survival (PFS) was 8.3 months, with a disease control rate (DCR) of 82%.
- Confirmed overall response rate (ORR) was 36%.
- Only two categories of Grade 3 or higher treatment-related adverse events occurred in at least 10% of participants.
- 84% of participants maintained or gained weight at three months.
- First patient dosing in the global Phase 3 MAPKeeper 301 trial is expected in mid-2026.
- Topline readout for the Phase 3 MAPKeeper 301 trial is expected in mid-2028.
Price Impact
More from IMRX